Hellenic Dynamics (LON: HELD) is up 12% in London this morning. They've announced a contract grow operation with a distributor in Germany. We can see that this might be a decent use of infrastructure already built, of gaining throughput and so on. But we're unconvinced that it's going to be a major profit driver. But then we're unconvinced about the cannabis market as a whole. Sure, people like it, will pay for it. It's now legal - some places medical, some leisure markets - and so on. It's just that we don't see growing what is, quite literally, a weed in many parts of the world as becoming a wildly profitable occupation.
As we've said before about Hellenic Dynamics: “Now, we think that the legalisation of cannabis is a great idea. People should be able to smoke if they wish, why leave that business in the hands of illegal thugs? But that doesn't mean we think that legalisation has been done right. Further, we're deeply unsure that anyone at all is going to make a profit.
We can just about imagine that people growing in really low costs places - Swaziland perhaps - will be able to eke out a margin. But this is, in the production sense, just a form of farming. And there really isn't anyone out there who makes a good profit margin from farming. Given that anyone with a field and a spade can go farming, why should there be any profits available?”

Hellenic Dynamics share price from London Stock Exchange
Calculations of what the real price will be in a proper global marketplace have been done and they don't seem to leave much room for a profit to people trying to grow in Europe. Rather like - in fact exactly like - people trying to grow tobacco in Europe.
“So, yes, I feel confident in predicting that a pack of fully legal cannabis joints, one that is able to benefit from the full effects of global capitalism, would cost something like 50 cents instead of the predicted $50.”
That really doesn't leave much room for a profit at European production costs.
Now, the deal today is: “Under the MoU, Hellenic Dynamics will grow and supply medical cannabis flowers from Demecan provided cultivars in an indoor cultivation area of 1,000 square meters capable of producing circa 1,200 kg of medical cannabis flowers per annum under Good Agricultural and Collection Practice ("GACP"). Demecan will then process the delivered flowers in its own EU-GMP facilities for onward sale to the German market.”
Well, you know, OK and maybe. But we don't see contract cultivation as being a long term profitable enterprise. Cannabis is simply too simple a thing to grow for that.



